幼年脊柱关节炎4年观察病程:GESPIC幼年部分
德国GESPIC队列前瞻性随访118例幼年脊柱关节炎患者4年,多数起病为外周关节炎。85%患者至少获得一次≥6个月药物缓解,46%实现≥12个月无药缓解;4年末23%无药缓解,57%仍有活动性疾病。起病有炎性背痛者持续风险较高。
要点
- 85%患者随访期间至少一次≥6个月药物缓解,46%实现≥12个月无药缓解。
- 4年末仅23%无药缓解,57%仍有活动性疾病,提示成年期复发或持续风险高。
- 起病有炎性背痛者4年后持续概率53%,高于外周关节炎持续概率29%。
核心结论
- 约四分之一幼年脊柱关节炎患者4年后无药缓解,但复发或持续至成年的可能性大,尤其起病有炎性背痛者。
研究设计与样本
- 德国脊柱关节炎起始队列(GESPIC)幼年部分前瞻性随访4年,纳入起病年龄≤16岁的幼年脊柱关节炎患者118例,来自2个研究中心。
主要发现
- 118例患者中73%为男性,66% HLA-B27阳性,平均年龄13.5岁,平均症状持续时间2.2年。
- 52%患者符合国际风湿病学联盟分类标准中附着点炎相关关节炎亚组。
- 入组时75.4%有活动性外周关节炎,19.5%有炎性背痛,16.1%有附着点炎。
- 4年随访期间85%患者至少有一次≥6个月药物缓解,46%实现≥12个月无药缓解,其中68%维持该状态、32%恶化。
- 4年末23%患者无药缓解,57%仍有活动性疾病;起病有外周关节炎者4年后外周关节炎概率29%,起病有炎性背痛者炎性背痛持续概率53%。
关键数值与推荐
- 52%幼年脊柱关节炎患者被国际风湿病学联盟分类标准中附着点炎相关关节炎亚组覆盖。
临床怎么用
- 幼年脊柱关节炎需长期随访,即使实现无药缓解也应警惕复发,尤其起病有炎性背痛者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the course and the 4-year outcome of juvenile spondyloarthritis (jSpA). METHODS: Patients with a diagnosis of jSpA and an age at onset ≤16 years were included in the German Spondyloarthritis Inception cohort (GESPIC) and followed up prospectively for 4 years. RESULTS: 118 patients (73% men, 66% HLA-B27 positive, mean age 13.5 years, mean symptom duration 2.2 years) were enrolled in 2 study centres: 52% of patients with jSpA were captured by the enthesitis-related arthritis subgroup of the International League of Associations for Rheumatology classification criteria. At inclusion, the majority of patients had active peripheral arthritis (75.4%), followed by inflammatory back pain (IBP) (19.5%) and enthesitis (16.1%). There was a significant improvement in clinical manifestations and in patient-reported outcomes over time. During the 4-year follow-up, 85% of the patients had at least 1 period of remission on drug ≥6 months, and 46% of the patients achieved remission ≥12 months without medication, of whom 68% kept this status and 32% worsened. At the end of 4 years of observation, 23% of the patients were in remission without medication, but 57% still suffered from active disease. Patients with peripheral arthritis had a likelihood of 29% for having peripheral arthritis after 4 years, whereas the likelihood of IBP persistence was 53% for those with IBP at enrolment. CONCLUSIONS: Although 1 quarter of patients with jSpA achieved remission off medication after 4 years, the likelihood of having recurrent or persistent disease into adulthood is substantial, particularly for jSpA with IBP. TRIAL REGISTRATION NUMBER: NCT 01277419.
引用
- Weiß A, Minden K, Listing J, et al. Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC. RMD Open. 2017. PMID: 28405472. doi:10.1136/rmdopen-2016-000366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。